The EDGE

E Donnall Thomas (1920–2012)

Robert Peter Gale

Leukemia 2013 27: 259; 10.1038/leu.2012.330

Reviews

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia

A Y H Leung, C-H Man and Y-L Kwong

Leukemia 2013 27: 260-268; advance online publication, July 16, 2012; 10.1038/leu.2012.195

Role and potential for therapeutic targeting of MYB in leukemia

D R Pattabiraman and T J Gonda

Leukemia 2013 27: 269-277; advance online publication, August 9, 2012; 10.1038/leu.2012.225

Original Articles

MOLECULAR TARGETS FOR THERAPY

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation

Y Bai, G Bandara, E Ching Chan, I Maric, O Simakova, S N Bandara, W-P Lu, S C Wise, D L Flynn, D D Metcalfe, A M Gilfillan and T M Wilson

Leukemia 2013 27: 278-285; advance online publication, July 31, 2012; 10.1038/leu.2012.218

THERAPY

Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction

J Kanda, T Ichinohe, S Kato, N Uchida, S Terakura, T Fukuda, M Hidaka, Y Ueda, T Kondo, S Taniguchi, S Takahashi, T Nagamura-Inoue, J Tanaka, Y Atsuta, K Miyamura and Y Kanda on behalf of the Donor/Source Working Group and HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation

Leukemia 2013 27: 286-294; advance online publication, July 18, 2012; 10.1038/leu.2012.203

ACUTE LEUKEMIAS

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

S Krentz, J Hof, A Mendioroz, R Vaggopoulou, P Dörge, C Lottaz, J C Engelmann, T W L Groeneveld, G Körner, K Seeger, C Hagemeier, G Henze, C Eckert, A von Stackelberg and R Kirschner-Schwabe

Leukemia 2013 27: 295-304; advance online publication, June 13, 2012; 10.1038/leu.2012.155

Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL

L Lhermitte, R Ben Abdelali, P Villarèse, N Bedjaoui, V Guillemot, A Trinquand, M Libura, A S Bedin, A Petit, H Dombret, G Leverger, N Ifrah, O Hermine, E Macintyre and V Asnafi

Leukemia 2013 27: 305-314; advance online publication, July 3, 2012; 10.1038/leu.2012.177

Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells

R Wang, L Xia, J Gabrilove, S Waxman and Y Jing

Leukemia 2013 27: 315-324; advance online publication, July 3, 2012; 10.1038/leu.2012.180

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors

C Fialin, C Larrue, F Vergez, J E Sarry, S Bertoli, V Mansat-De Mas, C Demur, E Delabesse, B Payrastre, S Manenti, S Roche and C Récher

Leukemia 2013 27: 325-335; advance online publication, August 20, 2012; 10.1038/leu.2012.240

γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin

R G Morgan, L Pearn, K Liddiard, S L Pumford, A K Burnett, A Tonks and R L Darley

Leukemia 2013 27: 336-343; advance online publication, August 3, 2012; 10.1038/leu.2012.221

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation

X Lin, K L Rice, M Buzzai, E Hexner, F F Costa, O Kilpivaara, A Mullally, M B Soares, B L Ebert, R Levine and J D Licht

Leukemia 2013 27: 344-352; advance online publication, August 6, 2012; 10.1038/leu.2012.224

CYTOGENETICS AND MOLECULAR GENETICS

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance

F G Rücker, A C Russ, S Cocciardi, H Kett, R F Schlenk, U Botzenhardt, C Langer, J Krauter, S Fröhling, B Schlegelberger, A Ganser, P Lichter, T Zenz, H Döhner, K Döhner and L Bullinger

Leukemia 2013 27: 353-361; advance online publication, July 19, 2012; 10.1038/leu.2012.208

CHRONIC LYMPHOCYTIC LEUKEMIA

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome

J R Brown, H T Kim, P Armand, C Cutler, D C Fisher, V Ho, J Koreth, J Ritz, C Wu, J H Antin, R J Soiffer, J G Gribben and E P Alyea

Leukemia 2013 27: 362-369; advance online publication, August 14, 2012; 10.1038/leu.2012.228

MINIMAL RESIDUAL DISEASE

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

R Garand, K Beldjord, H Cavé, C Fossat, I Arnoux, V Asnafi, Y Bertrand, M-L Boulland, C Brouzes, E Clappier, E Delabesse, T Fest, F Garnache-Ottou, F Huguet, M-C Jacob, E Kuhlein, S Marty-Grès, A Plesa, N Robillard, M Roussel, J Tkaczuk, H Dombret, E Macintyre, N Ifrah, M C Béné and A Baruchel

Leukemia 2013 27: 370-376; advance online publication, August 16, 2012; 10.1038/leu.2012.234

IMMUNOLOGY

Immunosuppressive CD14⁺HLA-DR^low/neg IDO⁺ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation

D Mougiakakos, R Jitschin, L von Bahr, I Poschke, R Gary, B Sundberg, A Gerbitz, P Ljungman and K Le Blanc

Leukemia 2013 27: 377-388; advance online publication, July 25, 2012; 10.1038/leu.2012.215

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements

M Nishi, M Eguchi-Ishimae, Z Wu, W Gao, H Iwabuki, S Kawakami, H Tauchi, T Inukai, K Sugita, Y Hamasaki, E Ishii and M Eguchi

Leukemia 2013 27: 389-397; advance online publication, August 24, 2012; 10.1038/leu.2012.242

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo

S C Nabinger, X J Li, B Ramdas, Y He, X Zhang, L Zeng, B Richine, J D Bowling, S Fukuda, S Goenka, Z Liu, G-S Feng, M Yu, G E Sandusky, H S Boswell, Z-Y Zhang, R Kapur and R J Chan

Leukemia 2013 27: 398-408; advance online publication, October 22, 2012; 10.1038/leu.2012.308

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION

Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5

D A Casolari, M Makri, C Yoshida, A Muto, K Igarashi and J V Melo

Leukemia 2013 27: 409-415; advance online publication, August 3, 2012; 10.1038/leu.2012.220

LYMPHOMA

Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis

L Mussolin, C Damm-Welk, M Pillon, M Zimmermann, G Franceschetto, K Pulford, A Reiter, A Rosolen and W Woessmann

Leukemia 2013 27: 416-422; advance online publication, July 18, 2012; 10.1038/leu.2012.205

MYELOMA

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

M A Dimopoulos, M Roussou, M Gkotzamanidou, N Nikitas, E Psimenou, D Mparmparoussi, C Matsouka, M Spyropoulou-Vlachou, E Terpos and E Kastritis

Leukemia 2013 27: 423-429; advance online publication, July 5, 2012; 10.1038/leu.2012.182

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

M A Hurchla, A Garcia-Gomez, M C Hornick, E M Ocio, A Li, J F Blanco, L Collins, C J Kirk, D Piwnica-Worms, R Vij, M H Tomasson, A Pandiella, J F San Miguel, M Garayoa and K N Weilbaecher

Leukemia 2013 27: 430-440; advance online publication, July 5, 2012; 10.1038/leu.2012.183

The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival

K S Bommert, M Effenberger, E Leich, M Küspert, D Murphy, C Langer, R Moll, S Janz, A Mottok, S Weissbach, A Rosenwald, R Bargou and K Bommert

Leukemia 2013 27: 441-450; advance online publication, July 9, 2012; 10.1038/leu.2012.185

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells

M Bolzoni, G Donofrio, P Storti, D Guasco, D Toscani, M Lazzaretti, S Bonomini, L Agnelli, A Capocefalo, B Dalla Palma, A Neri, F Nicolini, G Lisignoli, F Russo, S Colla, F Aversa and N Giuliani

Leukemia 2013 27: 451-463; advance online publication, July 11, 2012; 10.1038/leu.2012.190

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

H Tamura, M Ishibashi, T Yamashita, S Tanosaki, N Okuyama, A Kondo, H Hyodo, E Shinya, H Takahashi, H Dong, K Tamada, L Chen, K Dan and K Ogata

Leukemia 2013 27: 464-472; advance online publication, July 25, 2012; 10.1038/leu.2012.213

Minor clone provides a reservoir for relapse in multiple myeloma

F Magrangeas, H Avet-Loiseau, W Gouraud, L Lodé, O Decaux, P Godmer, L Garderet, L Voillat, T Facon, A M Stoppa, G Marit, C Hulin, P Casassus, M Tiab, E Voog, E Randriamalala, K C Anderson, P Moreau, N C Munshi and S Minvielle

Leukemia 2013 27: 473-481; advance online publication, August 9, 2012; 10.1038/leu.2012.226

Letters to the Editor

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

A Fasan, C Eder, C Haferlach, V Grossmann, A Kohlmann, F Dicker, W Kern, T Haferlach and S Schnittger

Leukemia 2013 27: 482-485; advance online publication, July 3, 2012; 10.1038/leu.2012.174

Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression

S Cialfi, R Palermo, S Manca, S Checquolo, D Bellavia, M Pelullo, R Quaranta, C Dominici, A Gulino, I Screpanti and C Talora

Leukemia 2013 27: 485-488; advance online publication, July 13, 2012; 10.1038/leu.2012.192

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

D B Watkins, T P Hughes, D L White and R J D'Andrea

Leukemia 2013 27: 489-490; advance online publication, July 13, 2012; 10.1038/leu.2012.193

Telomeres and chromosomal instability in chronic lymphocytic leukemia

L Véronèse, O Tournilhac, M Callanan, N Prie, F Kwiatkowski, P Combes, M Chauvet, F Davi, L Gouas, P Verrelle, R Guièze, P Vago, J O Bay and A Tchirkov

Leukemia 2013 27: 490-493; advance online publication, July 13, 2012; 10.1038/leu.2012.194

Partial 17q gain resulting from isochromosomes, unbalanced translocations and complex rearrangements is associated with gene overexpression, older age and shorter overall survival in high hyperdiploid childhood acute lymphoblastic leukemia

E Herou, A Biloglav, B Johansson and K Paulsson

Leukemia 2013 27: 493-496; advance online publication, July 17, 2012; 10.1038/leu.2012.198

Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype

U Bacher, T Haferlach, T Alpermann, W Kern, S Schnittger and C Haferlach

Leukemia 2013 27: 496-500; advance online publication, July 17, 2012; 10.1038/leu.2012.200

Encapsulated mesenchymal stem cells for in vivo immunomodulation

L Zanotti, A Sarukhan, E Dander, M Castor, J Cibella, C Soldani, A E Trovato, C Ploia, G Luca, M Calvitti, F Mancuso, I Arato, M Golemac, N Jonjic, A Biondi, R Calafiore, M Locati, G D'Amico and A Viola

Leukemia 2013 27: 500-503; advance online publication, July 18, 2012; 10.1038/leu.2012.202

Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations

A Dupuis, M P Gaub, M Legrain, B Drenou, L Mauvieux, P Lutz, R Herbrecht, S Chan and P Kastner

Leukemia 2013 27: 503-507; advance online publication, July 18, 2012; 10.1038/leu.2012.204

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry Open

E Matutes, A G Bosanquet, R Wade, S M Richards, M Else and D Catovsky

Leukemia 2013 27: 507-510; advance online publication, July 19, 2012; 10.1038/leu.2012.209

Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia

R Rosenquist, H Ehrencrona, H Hasle, J Palle and M Kanduri

Leukemia 2013 27: 510-512; advance online publication, August 31, 2012; 10.1038/leu.2012.250

NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia

L Mansouri, N Cahill, R Gunnarsson, K E Smedby, E Tjönnfjord, H Hjalgrim, G Juliusson, C Geisler and R Rosenquist

Leukemia 2013 27: 512-514; advance online publication, November 6, 2012; 10.1038/leu.2012.307

Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma

A J Greenberg, A M Lee, D J Serie, S K McDonnell, J R Cerhan, M Liebow, D R Larson, C L Colby, A D Norman, R A Kyle, S Kumar, S V Rajkumar, R B Diasio, S L Slager and C M Vachon

Leukemia 2012 27: 515-516; advance online publication, August 16, 2012; 10.1038/leu.2012.232